Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Evens

Showing results (31-40 of 224) with videos related to

Pageof 23
Sort By:
Hematology/Oncology Clinics of North America|November 28, 2016
Gray Zone Lymphoma: Current Diagnosis and Treatment OptionsMonika Pilichowska, Athena Kritharis, Andrew M Evens
Cancer Treatment and Research|May 18, 2006
T-cell non-Hogdkin's lymphomaAndrew M Evens, Christiane Querfeld, Steven T Rosen
The Lancet. Haematology|April 14, 2018
Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?Kevin A David, Athena Kritharis, Andrew M Evens
Current Treatment Options in Oncology|January 25, 2008
Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic optionsKevin A David, Lauren Mauro, Andrew M Evens
Blood|September 15, 2021
Defining and treating high-grade B-cell lymphoma, NOSAdam J Olszewski, Habibe Kurt, Andrew M Evens
Best Practice & Research. Clinical Haematology|March 29, 2005
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) groupAndrew M Evens, Charles L Bennett, Stefano Luminari
Current Treatment Options in Oncology|June 22, 2005
Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignanciesAndrew M Evens, Lakshmi Balasubramanian, Leo I Gordon
Journal of the Massachusetts Dental Society|July 15, 2015
A Clinico-Pathologic Correlation. Burkitt's lymphoma)Ray English, Alireza Ashrafi, Andrew M Evens, et al.
Current Hematologic Malignancy Reports|June 6, 2013
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategiesZeina Al-Mansour, Beverly P Nelson, Andrew M Evens
Leukemia Research|July 6, 2004
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and futureAndrew M Evens, Martin S Tallman, Ronald B Gartenhaus
Pageof 23

Showing results (31-40 of 224) with videos related to

Sort By:
Pageof 23
Hematology/Oncology Clinics of North America|November 28, 2016
Gray Zone Lymphoma: Current Diagnosis and Treatment OptionsMonika Pilichowska, Athena Kritharis, Andrew M Evens
Cancer Treatment and Research|May 18, 2006
T-cell non-Hogdkin's lymphomaAndrew M Evens, Christiane Querfeld, Steven T Rosen
The Lancet. Haematology|April 14, 2018
Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma?Kevin A David, Athena Kritharis, Andrew M Evens
Current Treatment Options in Oncology|January 25, 2008
Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic optionsKevin A David, Lauren Mauro, Andrew M Evens
Blood|September 15, 2021
Defining and treating high-grade B-cell lymphoma, NOSAdam J Olszewski, Habibe Kurt, Andrew M Evens
Best Practice & Research. Clinical Haematology|March 29, 2005
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) groupAndrew M Evens, Charles L Bennett, Stefano Luminari
Current Treatment Options in Oncology|June 22, 2005
Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignanciesAndrew M Evens, Lakshmi Balasubramanian, Leo I Gordon
Journal of the Massachusetts Dental Society|July 15, 2015
A Clinico-Pathologic Correlation. Burkitt's lymphoma)Ray English, Alireza Ashrafi, Andrew M Evens, et al.
Current Hematologic Malignancy Reports|June 6, 2013
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategiesZeina Al-Mansour, Beverly P Nelson, Andrew M Evens
Leukemia Research|July 6, 2004
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and futureAndrew M Evens, Martin S Tallman, Ronald B Gartenhaus
Pageof 23